Asia-Pacific Molecular Diagnostics Market (2025-2032)
The Asia-Pacific Molecular Diagnostics Market is projected to reach $11.87 billion by 2032, at a CAGR of 7.2% from 2025 to 2032.
- Published
- Jan 2025
- Pages
- 200
- Format
- PDF + Excel
- Report ID
- MRHC - 1041036
- Base year
- 2024
- 2032 · FORECAST
- $11.87B
- 2032
- $11.87B
- CAGR 2025–2032
- 7.2%
2024 baseline · 2025–2032 forecast at 7.2% CAGR · hover a bar for the value
Key highlights
In 2025, the Kits & Reagents Segment is Expected to Dominate the Molecular Diagnostics Market
In 2025, the Laboratory Tests Segment is Expected to Dominate the Molecular Diagnostics Market
In 2025, the Polymerase Chain Reaction (PCR) Segment is Expected to Dominate the Asia-Pacific Molecular Diagnostics Market
In 2025, the Infectious Diseases Segment is Expected to Dominate the Asia-Pacific Molecular Diagnostics Market
In 2025, the Hospitals & Clinics Segment is Expected to Dominate the Molecular Diagnostics Market
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025–2032 |
| Market Size (2032) | USD 11.87 billion |
| CAGR (2025–2032) | 7.2% |
| Format | PDF, Excel & Cloud Portal · 200 pages |
| Segments Covered | By Product & Service: Kits & Reagents, Instruments, Software & Services · By Test Type: Laboratory Tests, Point of Care Tests · By Technology: Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Isothermal Nucleic Acid Amplification Technology (INAAT), Microarrays, Sequencing, Mass Spectrometry · By Application: Infectious Diseases COVID-19, Hepatitis, HIV, Chlamydia trachomatis/ Neisseria gonorrhoeae (CT/NG), Human papillomavirus (HPV), Tuberculosis, Influenza, Healthcare-associated Infections (HAIs), Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Lymphoma, Leukemia · By End User: Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, Other End Users |
| Countries Covered | Asia-Pacific (China, Japan, India, Australia, Singapore, Indonesia, Malaysia, South Korea, New Zealand, Rest of Asia-Pacific) |
| Key Companies | F. Hoffmann-La Roche Ltd, Hologic, Inc. (U.S.), QIAGEN N.V., Danaher Corporation (U.S.), Becton, Dickinson and Company (BD) (U.S.), Siemens Healthineers AG, DiaSorin S.p.A, Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), Seegene, Inc. |
Report overview
Segments covered: product & service, test type, technology, application, end user. Regions: Asia-Pacific.
Molecular diagnostics help detect the targeted genetic material in human, viral, and bacterial genomes. Molecular diagnostic tests are increasingly used in many areas, including infectious diseases, oncology, and clinical genetics. Advancements in molecular diagnostics continue to improve the accuracy and speed of diagnosis. Molecular diagnostics is becoming an essential aspect of patient-tailored interventions and therapeutics. The molecular diagnostics market comprises advanced products and technologies used by medical professionals for patient management, from diagnosis to treatment, primarily focusing on areas such as infectious diseases and cancer.
Asia-Pacific molecular diagnostics market is growing due to the rising healthcare expenditure, growing use of PoC diagnostics tests, technological advancements in molecular diagnostics, and increasing funding for R&D in molecular diagnostics. Furthermore, increasing focus on companion diagnostics to offer new growth potential is expected to offer immense growth opportunities for market expansion. However, stringent regulatory frameworks and the high cost of molecular diagnostics tests are expected to restrain the growth of this market to some extent. In addition, the lack of skilled professionals is a major challenge to the market’s growth.
Report infographic
Market dynamics
4 factors across 1 forceIn July 2021,
MiRXES Pte Ltd (Singapore) raised USD 77 million in Series C funding, led by CR-CP Life Science Fund (Thailand) and Keytone Ventures. The funds are being used to deliver cancer early detection tests and preventive healthcare across the globe.
In September 2022,
Molbio Diagnostics Pvt. Ltd. (India) raised USD 85 million, led by Singapore-based Temasek. The funds are being used to accelerate the ability of Molbio to develop near-care technologies, expand its proprietary platform, and address clinic need gaps globally. Molbio allows rapid, cost-effective, and precise molecular diagnosis at the point of care.
In August 2025,
Neurophth Therapeutics (China) raised USD 95 million in Series C+ funding, led by Wuhan Optical Valley Financial Holding Group (China), Yangtze River-CMB International Industry Fund, Guangzhou Jinkong Fund, Hubei KTLC, and Wuhan Hi-Tech Holding Group (China). The funds will be used to develop gene therapies for ophthalmic diseases.
Technological Advancements in Molecular Diagnostics Driving the Growth of the Market
The healthcare landscape is constantly changing due to innovations in medical technologies. In recent years, companies have been focused on developing advanced diagnostic kits that can allow faster results than traditional kits. These advanced kits enable healthcare providers and caregivers to make crucial medical decisions promptly. Companies have been developing ultra-fast PCR kits to minimize the time required to generate test results. For instance, In November 2021, Genes2Me (India) launched an RT-PCR kit for COVID-19 that shows results in 40 minutes without any instrument and RNA extraction kit. Similarly, Genesystem (South Korea) launched the ultra-fast GENECHECKER UF-300 real-time PCR system to detect novel coronavirus infections. This ultra-fast PCR kit received the CE mark approval in April 2020. The total turnaround time using the GENECHECKER UF-300 real-time PCR platform is 45 minutes.
Furthermore, integrating digital technologies in clinical and ambulatory settings helps improve doctors’ and physicians’ ability to reach an initial diagnosis. Also, the digitalization of diagnostic services helps document and analyze patient data and test results, which minimizes human error and makes treatment and care pathways more consistent. Hence, an increasing number of healthcare providers are adopting digitally compatible diagnostic systems and devices to store patient data and view patients’ medical histories instantly.
Table of contents
13 chapters · 108 sections · 200 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Product & Service | Kits & Reagents | — |
| By All the Test Types Covered in the Report | Laboratory Tests | — |
| By All the Technologies Covered in the Report | Polymerase Chain Reaction (PCR) | — |
| By All the Applications Covered in the Report | Infectious Diseases | — |
| By All the end Users Covered in the Report | Hospitals & Clinics | — |
By Product & Service
- The Kits & Reagents Segment is Expected to Dominate the Molecular Diagnostics Market
- Among all the products & services covered in the report, in 2025, the kits & reagents segment is expected to account for the largest share of the Asia-Pacific molecular diagnostics market.
- Recurrent use of assays & kits in the detection of various diseases through molecular diagnostics, rise in product approvals, and technological advancements in molecular techniques contribute to the large market share of this segment.
By All the Test Types Covered in the Report
- The Laboratory Tests Segment is Expected to Dominate the Molecular Diagnostics Market
- The lab tests segment is expected to account for the largest share of the Asia-Pacific molecular diagnostics market.
- Lab tests are traditionally used in hospitals and diagnostic centers and are widely accepted.
- Laboratory testing is a traditional approach in which the clinician takes a sample from the patient and sends it to the laboratory for processing and testing.
- It has higher accuracy and reliability when compared to point-of-care testing.
- The laboratory equipment and analyzers have high sensitivity and specificity.
- These factors drive the adoption of laboratory tests.
By All the Technologies Covered in the Report
- The Polymerase Chain Reaction (PCR) Segment is Expected to Dominate the Asia-Pacific Molecular Diagnostics Market
- Among all the technologies covered in the report, in 2025, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the Asia-Pacific molecular diagnostics market.
- The large market share of this segment is attributed to its benefits, such as the ability to test for multi-drug resistance, ease of quantification, greater sensitivity, rapid results compared to traditional diagnostics methods, and launches of PCR kits in the region for the qualitative and quantitative detection of COVID infections.
- In May 2021, Cipla Inc. (India) launched ViraGen, an RT-PCR test kit for the detection of coronavirus.
By All the Applications Covered in the Report
- The Infectious Diseases Segment is Expected to Dominate the Asia-Pacific Molecular Diagnostics Market
- Among all the applications covered in the report, in 2025, the infectious diseases segment is expected to account for the largest share of the Asia-Pacific molecular diagnostics market.
- Infectious diseases are transmissible or communicable illnesses that spread quickly in some areas and become epidemics.
- It is crucial to quickly diagnose initial infections and prevent further spread through in vitro diagnosis.
- The growing prevalence of infectious diseases such as HIV, the growing availability of rapid and self-diagnostic tests for HIV, the rising funds for infectious disease diagnostic research activities, the emergence of the COVID-19 pandemic, and the growing need to detect and treat infectious diseases have led to the emergence of new technologies such as molecular systems and PoC, microarrays, and next-generation sequencing are the factors attributed to the segment’s large market share.
By All the end Users Covered in the Report
- The hospitals & clinics segment is expected to account for the largest share of the Asia-Pacific molecular diagnostics market.
- The segment's large market share is attributed to the increased number of hospitalizations due to various diseases requiring molecular diagnosis, the high prevalence of healthcare-associated infections (HAIs) among individuals, growing awareness of the importance of molecular diagnostics and governments of various countries in the region are supporting hospitals by providing funds.
- In February 2020, the Maharashtra government (India) announced that it would set up a COVID-19 testing facility at Kasturba Hospital (Mumbai) to reduce the burden of testing at the National Institute of Virology (Pune).
Geographic analysis
Asia-Pacific
Largest shareAmong all the countries covered in the report, in 2025, China is expected to account for the largest share of the Asia-Pacific molecular diagnostics market due to the rising geriatric population and growing prevalence of infectious & chronic diseases. The elderly population is more prone to chronic and infectious diseases due to immune dysfunction, malnutrition, and physiological changes associated with aging. The rising burden of diseases can directly affect the social and economic status of a country. Thus, it is necessary to adopt early diagnostic procedures to minimize the burden of these diseases. The high population growth, the rise in the geriatric population, and the rising prevalence of diseases have increased the demand for molecular diagnostic products in the country. China: Largest Share of the Market
Competitive landscape
- F. Hoffmann-La Roche Ltd · Switzerland
- Hologic, Inc. (U.S.)
- QIAGEN N.V. · Netherlands
- Danaher Corporation (U.S.)
- Becton
- Dickinson and Company (BD) (U.S.)
- Siemens Healthineers AG · Germany
- DiaSorin S.p.A · Italy
- Abbott Laboratories (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Illumina, Inc. (U.S.)
- Seegene, Inc. · South Korea
Frequently asked questions
The Asia-Pacific molecular diagnostics market study covers the market sizes and forecasts for various molecular diagnostics products used in the healthcare sector. The report involves the value analysis of various segments and subsegments of the Asia-Pacific molecular diagnostics market at the country level.
Cite this report
Meticulous Research. (2025). Asia-Pacific Molecular Diagnostics Market - Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 1041036). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/asia-pacific-molecular-diagnostics-market-5719